Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide deficiency

M V Pokrovskii; V I Kochkarov; T G Pokrovskaya; E B Artyushkova; E N Pashin; L M Danilenko; M V Korokin; A S Belous; L V Korokina; V A Malykhin; Ya I Zaloznykh; M S Brusnik; E S Zhavbert

doi:10.1007/s10517-010-0751-4

Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide deficiency

Bull Exp Biol Med. 2009 Sep;148(3):514-7. doi: 10.1007/s10517-010-0751-4.

[Article in English, Russian]

Authors

M V Pokrovskii¹, V I Kochkarov, T G Pokrovskaya, E B Artyushkova, E N Pashin, L M Danilenko, M V Korokin, A S Belous, L V Korokina, V A Malykhin, Ya I Zaloznykh, M S Brusnik, E S Zhavbert

Affiliation

¹ Kursk State Medical University, Federal Agency for Health Care and Social Development.

PMID: 20396727
DOI: 10.1007/s10517-010-0751-4

Abstract

Experimental NO deficiency induced by L-NAME injection led to the development of arterial hypertension, endothelial dysfunction, and cardiomyocyte hypertrophy and reduced blood content of nitrates and nitrites. Impaza, NO donors, activators of NO-synthase, antioxidants, and antihypertensive preparations produced endothelium-protective effect of different degree.

Publication types

Comparative Study

MeSH terms

Animals
Antibodies / therapeutic use*
Antihypertensive Agents / therapeutic use
Antioxidants / therapeutic use
Endothelium, Vascular / drug effects*
Hypertension / chemically induced
Hypertension / drug therapy
Male
NG-Nitroarginine Methyl Ester / pharmacology
Nitrates / metabolism
Nitric Oxide / deficiency*
Nitric Oxide Donors / therapeutic use
Nitrites / metabolism
Rats
Rats, Wistar
Resveratrol
Stilbenes / therapeutic use

Substances

Antibodies
Antihypertensive Agents
Antioxidants
IMPAZA
Nitrates
Nitric Oxide Donors
Nitrites
Stilbenes
Nitric Oxide
Resveratrol
NG-Nitroarginine Methyl Ester